Opus Genetics, Inc. Common Stock IRD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:48:15.802Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:01.843377594Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T00:48:15.352621+00:00
Opus Genetics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.70 | 128.3% | 15.7% | |||
| 25Δ | 4.53 | 158.6% | 15.2% | |||
| 30Δ | 4.37 | 188.9% | 14.7% | |||
| 35Δ | 4.20 | 219.1% | 14.2% | |||
| 40Δ | 4.03 | 249.4% | 13.7% | |||
| 45Δ | 3.86 | 279.7% | 13.2% | |||
| 50Δ | 3.70 | 310.0% | 12.7% | |||
| 55Δ | 3.53 | 340.2% | 12.2% | |||
| 60Δ | 3.36 | 370.5% | 11.7% | |||
| 65Δ | 3.20 | 400.8% | 11.1% | 5.30 | 212.0% | 6.5% |
| 70Δ | 3.03 | 431.1% | 10.6% | 5.75 | 218.3% | 5.5% |
| 75Δ | 2.86 | 461.3% | 10.1% | 6.19 | 224.6% | 4.4% |
| 80Δ | 2.70 | 491.6% | 9.6% | 6.63 | 230.9% | 3.4% |
20Δ
- Pseudo strike
- 4.70
- IV
- 128.3%
- B/E move
- 15.7%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.53
- IV
- 158.6%
- B/E move
- 15.2%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 4.37
- IV
- 188.9%
- B/E move
- 14.7%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 4.20
- IV
- 219.1%
- B/E move
- 14.2%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 4.03
- IV
- 249.4%
- B/E move
- 13.7%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 3.86
- IV
- 279.7%
- B/E move
- 13.2%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 3.70
- IV
- 310.0%
- B/E move
- 12.7%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 3.53
- IV
- 340.2%
- B/E move
- 12.2%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.36
- IV
- 370.5%
- B/E move
- 11.7%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.20
- IV
- 400.8%
- B/E move
- 11.1%
- Pseudo strike
- 5.30
- IV
- 212.0%
- B/E move
- 6.5%
70Δ
- Pseudo strike
- 3.03
- IV
- 431.1%
- B/E move
- 10.6%
- Pseudo strike
- 5.75
- IV
- 218.3%
- B/E move
- 5.5%
75Δ
- Pseudo strike
- 2.86
- IV
- 461.3%
- B/E move
- 10.1%
- Pseudo strike
- 6.19
- IV
- 224.6%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- 2.70
- IV
- 491.6%
- B/E move
- 9.6%
- Pseudo strike
- 6.63
- IV
- 230.9%
- B/E move
- 3.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 150.50% | |
| 109.27% | |
| 102.73% |
Biotechnology
IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious…
More →IVA
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH),…
More →IVVD
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious…
More →JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer…
More →JAZZ
Description unavailable
More →JBIO
Description unavailable
More →